Tildrakizumab was approved by FDA in 2018 for: (A) Cystic fibrosis, (B) Migraine, (C) Hypeension, (D) Psoriasis
Answer is D. Tildrakizumab was approved by FDA in 2018 to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy